Optimal management of bone metastases in prostate cancer

Current Oncology Reports

Volumn 13, Issue 3, 2011, Pages 222-230

  Aljumaily, Raid ^a   Mathew, Paul ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Bone metastases; Management; Prostate cancer; Skeletal related events

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CATHEPSIN K; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR 9; MITOXANTRONE; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR INHIBITOR; PACLITAXEL; PLACEBO; PREDNISONE; PROVENGE; RADIOISOTOPE; RADIUM 223; SAMARIUM 153; SARACATINIB; STRONTIUM 89; SUNITINIB; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ARTICLE; BONE FRAGILITY; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CANCER CONTROL; CANCER MORTALITY; CASTRATION; CATARACT; COMORBIDITY; DIARRHEA; DISEASE COURSE; FEBRILE NEUTROPENIA; HUMAN; HYPOCALCEMIA; MORBIDITY; NEPHROTOXICITY; NEUTROPENIA; OSTEOBLAST; OSTEOCLAST; PROSTATE CANCER; QUALITY OF LIFE; THROMBOEMBOLISM;

ANDROSTENOLS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HUMANS; MALE; PROSTATIC NEOPLASMS; RANK LIGAND; TAXOIDS; TISSUE EXTRACTS;

EID: 79955883280     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0160-5     Document Type: Article

References (50)

1. Jemal A, Center MA, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19:1893-907.
2. Jemal A, Siegal R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol. 2005;23:8232-41. (Pubitemid 46211560)
4. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol. 2000;31:578-83. (Pubitemid 30323983)
5. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-68.
6. Norgaard M, Jensen AO, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162-7.
7. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22:941-50. (Pubitemid 351689875)
8. Welch HG, Black WC. Overdiagnosis in Cancer. J Natl Cancer Inst. 2010;102:605-13.
9. Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol. 2005;23:8186-91. (Pubitemid 46211553)
10. De Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate plus low-dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA- 301, a randomized double-blind placebo-controlled Phase III Study. Ann Oncol. 2010;21(suppl 8): Abstract LBA 5.
11. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and Pharmacokinetic Study of XRP6258, a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723-30.
12. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376:1147-54.
13. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
14. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336-41. (Pubitemid 32128538)
15. Tu SM, Mathew P, Wong FC, et al. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:3319-24.
16. Morris M, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:2436-42.
17. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomized, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587-94. (Pubitemid 46995621)
18. Kingsley LA, Fournier PGJ, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609-17. (Pubitemid 350058141)
19. Casimiro S, Guise T, Chirgwin J, et al. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol. 2009;310:71-81.
20. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53-62. This provides seminal insight into the mechanism of action of nitrogen-containing bisphosphonates.
21. Saad F, Gleason D, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-82. (Pubitemid 38807610)
22. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol. 2006;17:986-9. (Pubitemid 43778991)
23. Schneider A, Kalikin LM, Mattos AC, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 2005;146:1727-36. (Pubitemid 40396881)
24. Gomes Jr RR, Buttke P, Paul EM, Sikes RA. Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation. Clin Exp Metastasis. 2009;26:641-51.
25. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 Suppl):6213s-6s.
26. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. (Pubitemid 46698462)
27. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564-71.
28. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine n-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol. 2009;182:509-16. These results support biological activity of denosumab in zoledronic acid (4 mg)-resistant osteolysis.
29. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration resistant prostate cancer (abstract #4507). J Clin Oncol. 2010;28:18s. (suppl: abstr LBA4507). This is the first comparative study of denosumab and zoledronic acid in metastatic prostate cancer, leading to FDA approval of denosumab.
30. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007;18:1765-73. (Pubitemid 350119560)
31. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15(23):7421-8.
32. Lara Jr PN, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer drugs. 2009;20(3):179-84.
33. Araujo J, Mathew P, Armstrong AJ, et al. Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer: analysis of Study CA180-086. Eur J Cancer Suppl. 2009;7:415S (abstract 7028).
34. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21-8. (Pubitemid 40052322)
35. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959-66. (Pubitemid 350036854)
36. Armstrong AJ, Creel P, Turnbull J, et al. A Phase I-II study of docetaxel and atrasentan in men with castration-resistant meta-static prostate cancer. Clin Cancer Res. 2008;14:6270-6.
37. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin-A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II Trial. BJU. 2010;7:966-73.
38. Schelman WR, Liu G, Wilding G, et al. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 2009 Sep 19 (Epub ahead of print).
39. Ellis WJ, Vessella RL, Buhler KR, et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res. 1996;6:1039-48.
40. Li ZG, Mathew P, Yang J, et al. Androgen-receptor negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008;118:2697-710.
41. Kelly WK, Halabi S, Carducci MA, et al. A randomized, doubleblind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol. 2010;28:18s (suppl;abstr LBA4511).
42. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010;21:319-24.
43. Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007;13:5816-24. (Pubitemid 47583906)
44. Bradley DA, Daignault S, Ryan CJ, et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2010 Aug 10
45. Smith M, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-Deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55. This is the first study to demonstrate fracture risk reduction in men with nonmetastatic prostate cancer receiving hormonal therapy.
46. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316-21.
47. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess Full Rep. 2007;158:1-235.
48. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010;183:2200-5.
49. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925-34.
50. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007;70:315-9. (Pubitemid 47362256)